UniProtKB/Swiss-Prot Q6NTF7: Variant p.Gly105Arg

DNA dC->dU-editing enzyme APOBEC-3H
Gene: APOBEC3H
Feedback?

Variant information Variant position:

105 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Arginine (R) at position 105 (G105R, p.Gly105Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from glycine (G) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Polymorphism:

There are at least 4 different haplotypes in the human population (PubMed:18779051, PubMed:18945781). The allele A3H-var/haplotype 2 encodes a more stable protein which is able to block HIV-1 replication (PubMed:18779051, PubMed:18945781). The displayed allele (haplotype 1) is unstable and inefficient to block HIV-1 replication (PubMed:18779051, PubMed:18945781). Additional information on the polymorphism described.
Variant description:

In allele A3H-Var; haplotype 2; allele presenting a higher expression and which is more effective in retrotransposons and HIV-1 restriction; increases protein stability. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs139297 [ dbSNP | Ensembl ]

Sequence information Variant position:

105 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

200 The length of the canonical sequence.
Location on the sequence:

CSSCAWELVDFIKAHDHLNL G IFASRLYYHWCKPQQKGLRL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         CSSCAWELVDFIKAHDHLNLGIFASRLYYHWCKPQQKGLRL

Rhesus macaque                CPSCAGELVDFIKAHRHLNLRIFASRLYYHWRPNYQEGLLL

Cat                           CPFCAEELVAFVKDNPHLSLRIFASRLYVHWRWKYQQGLRH

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 200	DNA dC->dU-editing enzyme APOBEC-3H
Domain	4 – 126	CMP/dCMP-type deaminase
Binding site	85 – 85
Binding site	88 – 88
Mutagenesis	90 – 90	W -> A. Resistance to ubiquitination and degradation by an ECS complex hijacked by HIV-1 Vif.
Mutagenesis	94 – 94	D -> A. Resistance to ubiquitination and degradation by an ECS complex hijacked by HIV-1 Vif.
Mutagenesis	97 – 97	K -> Q. Increased ubiquitination and degradation by an ECS complex hijacked by HIV-1 Vif.
Mutagenesis	110 – 110	R -> E. Decreased DNA deaminase activity.
Mutagenesis	111 – 111	L -> A. Decreased DNA deaminase activity.
Mutagenesis	112 – 112	Y -> A. Decreased DNA deaminase activity.
Mutagenesis	113 – 113	Y -> A. Decreased DNA deaminase activity.
Mutagenesis	114 – 114	H -> A. Increased DNA deaminase activity.
Mutagenesis	115 – 115	W -> A. Increased DNA deaminase activity.
Mutagenesis	125 – 125	L -> R. Resistance to ubiquitination and degradation by an ECS complex hijacked by HIV-1 Vif.
Beta strand	102 – 110

Literature citations
A genome annotation-driven approach to cloning the human ORFeome.
Collins J.E.; Wright C.L.; Edwards C.A.; Davis M.P.; Grinham J.A.; Cole C.G.; Goward M.E.; Aguado B.; Mallya M.; Mokrab Y.; Huckle E.J.; Beare D.M.; Dunham I.;
Genome Biol. 5:R84.1-R84.11(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2); VARIANTS ASN-15 DEL; LEU-18; ARG-105 AND ASP-178; Antiretroelement activity of APOBEC3H was lost twice in recent human evolution.
OhAinle M.; Kerns J.A.; Li M.M.; Malik H.S.; Emerman M.;
Cell Host Microbe 4:249-259(2008)
Cited for: FUNCTION; SUBCELLULAR LOCATION; POLYMORPHISM; CHARACTERIZATION OF VARIANTS ASN-15 DEL AND ARG-105;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.